Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now Post author:Sam Post published:November 28, 2017 Post category:BioPharma Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace You Might Also Like Acorda Investor Urges for Company to Explore Sale August 6, 2017 Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million February 20, 2017 Maryland's Precision Medicine Group Lands $275M December 26, 2017
Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million February 20, 2017
